Cleared Traditional

BD BBL Sensi-Disc Ceftazidime Avibactam (30/20ug), Antimicrobial Susceptibility Test Disks (K152516) - FDA 510(k) Clearance

Class II Microbiology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K152516 · Becton, Dickinson and Company · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2015
Decision
40d
Days
Class 2
Risk

K152516 is an FDA 510(k) clearance for the BD BBL Sensi-Disc Ceftazidime Avibactam (30/20ug), Antimicrobial Susceptibili.... Classified as Susceptibility Test Discs, Antimicrobial (product code JTN), Class II - Special Controls.

Submitted by Becton, Dickinson and Company (Sparks, US). The FDA issued a Cleared decision on October 13, 2015 after a review of 40 days - a notably fast clearance cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.1620 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Becton, Dickinson and Company devices

Submission Details

510(k) Number K152516 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 03, 2015
Decision Date October 13, 2015
Days to Decision 40 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
62d faster than avg
Panel avg: 102d · This submission: 40d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code JTN Susceptibility Test Discs, Antimicrobial
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.1620
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - JTN Susceptibility Test Discs, Antimicrobial

All 99
Devices cleared under the same product code (JTN) and FDA review panel - the closest regulatory comparables to K152516.
HardyDisk Meropenem/Vaborbactam 20/10µg (MEV30)
K172621 · Hardy Diagnostics · Oct 2017
HardyDisk AST Delafloxacin 5 µg (DLX5)
K171975 · Hardy Diagnostics · Aug 2017
HardyDisk Ceftolozane/Tazobactam, (30/10 ug)-C/T40
K170127 · Hardy Diagnostics · Mar 2017
TELAVANCIN 30 UG, BBL SENSI-DISC
K100722 · Becton, Dickinson and Company · Mar 2010
FLUCONAZOLE 25UG BBL SENSI-DISC
K082271 · Becton, Dickinson & CO · Oct 2008
VORICONAZOLE 1UG BBL SENSI-DISC
K082272 · Becton, Dickinson & CO · Oct 2008